[Treatments for hepatitis virus C infections].
Pol
S
S
Unité d'Hépatologie et INSERM U-370, Hôpital Necker, 149, rue de Sèvres, 75743 Paris Cedex 15.
Fontaine
H
H
Vallet-Pichard
A
A
D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000821:virology; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000821:virology; D008113:Liver Neoplasms / Q000821:virology; D011379:Prognosis; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin; D000547:Amantadine